PaxMedica Announces Gold Sponsorship of The BRAIN Foundation’s Synchrony Symposia 2023
TARRYTOWN, NY / ACCESSWIRE / October 10, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the...
TARRYTOWN, NY / ACCESSWIRE / October 10, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the...
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s...
Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple...
BERKELEY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing...
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical...
-- Phase 3 Clinical Trials for AD109 Currently Enrolling Patients in the U.S.CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) --...
Preclinical Data Demonstrate CBX-15's Anti-Tumor Efficacy in Animal Models and Ability to Enhance Immunogenicity and Induce Immune Memory through pH-Based...
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)...
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE...
At the 36th European College of Neuropsychopharmacology congress (ECNP-2023)MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage...
- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria...
DURHAM, N.C., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced...
Collaboration with Uniklinikum Erlangen as 5th German research centerBERLIN, GERMANY / ACCESSWIRE / October 10, 2023 / Berlin Cures, a...
SANTA BARBARA, CA / ACCESSWIRE / October 9, 2023 / Santa Barbara Nutrients, Inc. is pleased to announce that our...
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),...
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of...
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire...